OMGAOmega Therapeutics, Inc.

Nasdaq omegatherapeutics.com


$ 1.37 $ 0.00 (0 %)    

Monday, 16-Sep-2024 14:47:12 EDT
QQQ $ 476.45 $ 0.48 (0.1 %)
DIA $ 417.33 $ 2.44 (0.59 %)
SPY $ 562.48 $ 0.83 (0.15 %)
TLT $ 101.29 $ 0.92 (0.92 %)
GLD $ 238.61 $ -0.02 (-0.01 %)
$ 1.33
$ 1.33 x 200
-- x --
-- - --
$ 1.22 - $ 6.30
144,616
na
73.36M
$ 1.68
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-30-2024 10-Q
2 05-06-2024 03-31-2024 10-Q
3 03-28-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-03-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 03-01-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-04-2022 03-31-2022 10-Q
11 03-10-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 09-10-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 omega-therapeutics-publishes-epigenomic-controller-otx-2002-preclinical-data-in-nature-communications

Treatment with OTX-2002 led to controlled downregulation of MYC gene expression and resulted in significant inhibition of tum...

 hc-wainwright--co-reiterates-buy-on-omega-therapeutics-maintains-12-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Omega Therapeutics (NASDAQ:OMGA) with a Buy and maintains $12 price ...

 wedbush-reiterates-outperform-on-omega-therapeutics-maintains-12-price-target

Wedbush analyst Robert Driscoll reiterates Omega Therapeutics (NASDAQ:OMGA) with a Outperform and maintains $12 price target.

 chardan-capital-maintains-buy-on-omega-therapeutics-lowers-price-target-to-6

Chardan Capital analyst Keay Nakae maintains Omega Therapeutics (NASDAQ:OMGA) with a Buy and lowers the price target from $7...

 raymond-james-initiates-coverage-on-omega-therapeutics-with-outperform-rating-announces-price-target-of-12

Raymond James analyst Ryan Deschner initiates coverage on Omega Therapeutics (NASDAQ:OMGA) with a Outperform rating and anno...

 hc-wainwright--co-reiterates-buy-on-omega-therapeutics-maintains-12-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Omega Therapeutics (NASDAQ:OMGA) with a Buy and maintains $12 price ...

 chardan-capital-maintains-buy-on-omega-therapeutics-maintains-7-price-target

Chardan Capital analyst Keay Nakae maintains Omega Therapeutics (NASDAQ:OMGA) with a Buy and maintains $7 price target.

 omega-therapeutics-q1-2024-gaap-eps-036-misses-035-estimate-sales-2360m-beat-1630m-estimate

Omega Therapeutics (NASDAQ:OMGA) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of ...

 hc-wainwright--co-reiterates-buy-on-omega-therapeutics-maintains-12-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Omega Therapeutics (NASDAQ:OMGA) with a Buy and maintains $12 price ...

 omega-therapeutics-presents-new-preclinical-data-supporting-the-potential-of-precision-epigenomic-control-at-aacr-2024

MYC-directed epigenomic controller exerts anti-tumor effect in preclinical models of EGFR inhibitor-resistant NSCLC regardles...

 piper-sandler-reiterates-overweight-on-omega-therapeutics-lowers-price-target-to-9

Piper Sandler analyst Edward Tenthoff reiterates Omega Therapeutics (NASDAQ:OMGA) with a Overweight and lowers the price tar...

 chardan-capital-maintains-buy-on-omega-therapeutics-lowers-price-target-to-7

Chardan Capital analyst Keay Nakae maintains Omega Therapeutics (NASDAQ:OMGA) with a Buy and lowers the price target from $1...

 omega-therapeutics-q4-2023-gaap-eps-037-beats-047-estimate

Omega Therapeutics (NASDAQ:OMGA) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION